Bladder cancer: Restaging TUR reduces recurrence and progression risk
Related Experiment Video
Updated: Jun 6, 2026

11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
1Sidney Kimmel Center for Prostate and Urologic Cancers, 353 East 68th Street, New York, NY 10021, USA. dalbagng@mskcc.org
Nature Reviews. Urology
|December 9, 2010
Abstract:
Transurethral resection (TUR) is widely used to manage early-stage bladder cancer. A recent study has confirmed that a second, or restaging, TUR is associated with a lower risk of progression and cancer-related death. Restaging TUR is therefore recommended as a standard of care in patients with stage T1 bladder cancer.
